Targeting the toll-like receptor/interleukin 1 receptor pathway in human diseases: Rational design of MYd88 inhibitors

Maria Loiarro, Vito Ruggiero, Claudio Sette

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Toll-like receptor (TLR)/interleukin (IL) 1 receptor (IL-1R) play a fundamental role in the immune response. These receptors are distributed in various cellular compartments and recognize different components of pathogens. All TLR/IL-1Rs, with the exception of TLR3, interact with MyD88, an intracellular adapter protein that triggers a signaling cascade that culminates in the expression of inflammatory genes. Because aberrant activation of TLR/IL-1Rs can promote the onset of inflammatory or autoimmune diseases and malignancies, this pathway has attracted considerable interest as a potential therapeutic target. Given the central role of MyD88 in TLR/IL-1R signaling, we set out different strategies to develop drugs that can block its function. Structural and functional analysis of the MyD88 domains allowed us to identify crucial residues required for MyD88 homodimerization. Moreover, we developed small cell-permeable peptides and peptidomimetic agents that inhibit MyD88 homodimerization and function. Our results pave the way for the development of new therapeutic drugs for the inhibition of MyD88-dependent signaling.

Original languageEnglish
Pages (from-to)222-226
Number of pages5
JournalClinical Lymphoma, Myeloma and Leukemia
Volume13
Issue number2
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Toll-Like Receptor 1
Interleukin-1 Receptors
Toll-Like Receptors
Interleukins
Peptidomimetics
Pharmaceutical Preparations
Autoimmune Diseases
Gene Expression
Peptides
Therapeutics
Neoplasms
Proteins

Keywords

  • Human diseases
  • MyD88
  • Signaling
  • Targeting
  • Toll-like receptor/interleukin 1 receptor

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Targeting the toll-like receptor/interleukin 1 receptor pathway in human diseases : Rational design of MYd88 inhibitors. / Loiarro, Maria; Ruggiero, Vito; Sette, Claudio.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 13, No. 2, 04.2013, p. 222-226.

Research output: Contribution to journalArticle

@article{4b041f38214c415e8cbf2fd3c0ac8073,
title = "Targeting the toll-like receptor/interleukin 1 receptor pathway in human diseases: Rational design of MYd88 inhibitors",
abstract = "Toll-like receptor (TLR)/interleukin (IL) 1 receptor (IL-1R) play a fundamental role in the immune response. These receptors are distributed in various cellular compartments and recognize different components of pathogens. All TLR/IL-1Rs, with the exception of TLR3, interact with MyD88, an intracellular adapter protein that triggers a signaling cascade that culminates in the expression of inflammatory genes. Because aberrant activation of TLR/IL-1Rs can promote the onset of inflammatory or autoimmune diseases and malignancies, this pathway has attracted considerable interest as a potential therapeutic target. Given the central role of MyD88 in TLR/IL-1R signaling, we set out different strategies to develop drugs that can block its function. Structural and functional analysis of the MyD88 domains allowed us to identify crucial residues required for MyD88 homodimerization. Moreover, we developed small cell-permeable peptides and peptidomimetic agents that inhibit MyD88 homodimerization and function. Our results pave the way for the development of new therapeutic drugs for the inhibition of MyD88-dependent signaling.",
keywords = "Human diseases, MyD88, Signaling, Targeting, Toll-like receptor/interleukin 1 receptor",
author = "Maria Loiarro and Vito Ruggiero and Claudio Sette",
year = "2013",
month = "4",
doi = "10.1016/j.clml.2013.02.003",
language = "English",
volume = "13",
pages = "222--226",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "2",

}

TY - JOUR

T1 - Targeting the toll-like receptor/interleukin 1 receptor pathway in human diseases

T2 - Rational design of MYd88 inhibitors

AU - Loiarro, Maria

AU - Ruggiero, Vito

AU - Sette, Claudio

PY - 2013/4

Y1 - 2013/4

N2 - Toll-like receptor (TLR)/interleukin (IL) 1 receptor (IL-1R) play a fundamental role in the immune response. These receptors are distributed in various cellular compartments and recognize different components of pathogens. All TLR/IL-1Rs, with the exception of TLR3, interact with MyD88, an intracellular adapter protein that triggers a signaling cascade that culminates in the expression of inflammatory genes. Because aberrant activation of TLR/IL-1Rs can promote the onset of inflammatory or autoimmune diseases and malignancies, this pathway has attracted considerable interest as a potential therapeutic target. Given the central role of MyD88 in TLR/IL-1R signaling, we set out different strategies to develop drugs that can block its function. Structural and functional analysis of the MyD88 domains allowed us to identify crucial residues required for MyD88 homodimerization. Moreover, we developed small cell-permeable peptides and peptidomimetic agents that inhibit MyD88 homodimerization and function. Our results pave the way for the development of new therapeutic drugs for the inhibition of MyD88-dependent signaling.

AB - Toll-like receptor (TLR)/interleukin (IL) 1 receptor (IL-1R) play a fundamental role in the immune response. These receptors are distributed in various cellular compartments and recognize different components of pathogens. All TLR/IL-1Rs, with the exception of TLR3, interact with MyD88, an intracellular adapter protein that triggers a signaling cascade that culminates in the expression of inflammatory genes. Because aberrant activation of TLR/IL-1Rs can promote the onset of inflammatory or autoimmune diseases and malignancies, this pathway has attracted considerable interest as a potential therapeutic target. Given the central role of MyD88 in TLR/IL-1R signaling, we set out different strategies to develop drugs that can block its function. Structural and functional analysis of the MyD88 domains allowed us to identify crucial residues required for MyD88 homodimerization. Moreover, we developed small cell-permeable peptides and peptidomimetic agents that inhibit MyD88 homodimerization and function. Our results pave the way for the development of new therapeutic drugs for the inhibition of MyD88-dependent signaling.

KW - Human diseases

KW - MyD88

KW - Signaling

KW - Targeting

KW - Toll-like receptor/interleukin 1 receptor

UR - http://www.scopus.com/inward/record.url?scp=84877619379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877619379&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2013.02.003

DO - 10.1016/j.clml.2013.02.003

M3 - Article

C2 - 23490990

AN - SCOPUS:84877619379

VL - 13

SP - 222

EP - 226

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 2

ER -